Figure 3From: Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?Data from seven registries in which the clinical outcome of patients receiving coronary stents treated with clopidogrel was compared with that of patients treated with ticlopidine. NS, not significant; MACE, major adverse cardiac events.Back to article page